

# IOTest® CD41-PE

REF A07781  
100 tests; 2 mL  
20 µL / test



IOTest  
Conjugated Antibody



ENGLISH	Specifications
Specificity	CD41
Clone	P2
Hybridoma	SP2/0-Ag14 x Balb/c
Immunogen	Human platelets
Immunoglobulin	IgG1
Species	Mouse
Source	Ascites
Purification	Protein A affinity chromatography
Fluorochrome	R Phycoerythrin (PE)
λ excitation	488 nm
Emission peak	575 nm
Buffer	PBS pH 7.2 plus 2 mg / mL BSA and 0.1% NaN <sub>3</sub>

## USE

This fluorochrome-conjugated antibody permits the identification and numeration of platelet and leucocytic populations expressing the CD41 antigen present in human biological samples using flow cytometry.

## PRINCIPLE

This test is based on the ability of specific monoclonal antibodies to bind to the antigenic determinants expressed by platelets or leucocytes.

Specific staining of leucocytes or platelets is performed by incubating the sample with the IOTest reagent. The red cells are then removed by lysis. The platelets and the leucocytes, which are unaffected by this process, are analyzed by flow cytometry.

The flow cytometer measures light diffusion and the fluorescence of cells. It makes possible the delimitation of the population of interest within the electronic window defined on a histogram, which correlates the orthogonal diffusion of light (Side Scatter or SS) and the diffusion of narrow-angle light (Forward Scatter or FS). Other histograms combining two of the different parameters available on the cytometer can be used as supports in the gating stage depending on the application chosen by the user.

The fluorescence of the so delimited platelets or leucocytes is analyzed in order to distinguish the positively-stained events from the unstained ones. The results are expressed as a percentage of positive events in relation to all the events acquired by the gating.

## EXAMPLES OF CLINICAL APPLICATIONS

Characterization and numeration of platelet or megakaryocyte populations expressing the CD41 molecule in diseases related to platelet aggregation and/or cellular adhesion. Follow-up and immunophenotyping of CD41+ cell populations in malignant blood dyscrasias (1). The CD41 molecule is an integral part of the CD41/CD61 complex, more commonly known by the name of the gpIIb-IIIa glycoprotein, which is absent or only very slightly expressed in the case of Glanzmann thrombasthenias (2).

## STORAGE AND STABILITY

The conjugated liquid forms must be kept at between 2 and 8°C and protected from light, before and after the vial has been opened.

Stability of closed vial: see expiry date on vial.

Stability of opened vial: the reagent is stable for 90 days.

## PRECAUTIONS

1. Do not use the reagent beyond the expiry date.
2. Do not freeze.

3. Let it come to room temperature (18 – 25°C) before use.
4. Minimize exposure to light.
5. Avoid microbial contamination of the reagents, or false results may occur.
6. Antibody solutions containing sodium azide (NaN<sub>3</sub>) should be handled with care. Do not take internally and avoid all contact with the skin, mucosa and eyes. Moreover, in an acid medium, sodium azide can form the potentially dangerous hydrazoic acid. If it needs to be disposed of, it is recommended that the reagent be diluted in a large volume of water before pouring it into the drainage system so as to avoid the accumulation of sodium azide in metal pipes and to prevent the risk of explosion.
7. All blood samples must be considered as potentially infectious and must be handled with care (in particular: the wearing of protective gloves, gowns and goggles).
8. Never pipette by mouth and avoid all contact of the samples with the skin, mucosa and eyes.
9. Blood tubes and disposable material used for handling should be disposed of in ad hoc containers intended for incineration.

## SAMPLES

Venous blood or bone marrow samples must be taken using sterile tubes containing an EDTA salt as the anticoagulant. The use of other anticoagulants is not recommended.

The samples should be kept at room temperature (18 – 25°C) and not shaken. The sample should be homogenized by gentle agitation prior to taking the test sample. The samples must be analyzed within 24 hours of venipuncture.

## METHODOLOGY

### NECESSARY MATERIAL NOT SUPPLIED

- Sampling tubes and material necessary for sampling.
- Automatic pipettes with disposable tips for 20, 100 and 500 µL.
- Plastic haemolysis tubes.
- Calibration beads: Flow-Set™ Fluorospheres (Ref. 6607007).
- Red cell lysis reagent with washing stage after lysis. For example: VersaLyse™ (Ref. A09777).
- Leucocyte fixation reagent. For example: IOTest 3 Fixative Solution (Ref. A07800).
- Isotypic control: IOTest reagent. IgG1-PE (Ref. A07796).
- Buffer (PBS: 0.01 M sodium phosphate; 0.145 M sodium chloride; pH 7.2).
- Centrifuge.
- Automatic agitator (Vortex type).
- Flow cytometer.

## PROCEDURE

**NOTE:** The procedure below is valid for standard applications. Sample and/or VersaLyse volumes for certain Beckman Coulter applications may be different. If such is the case, follow the instructions on the application's technical leaflet. For each sample analyzed, in addition to the test tube, one control tube is required in which the cells are mixed in the presence of the isotypic control (Ref. A07796).

1. Add 20 µL of specific IOTest conjugated antibody to each test tube, and 20 µL of the isotypic control to each control tube.
2. Add 100 µL of the test sample to both tubes. Vortex the tubes gently.
3. Incubate for 15 to 20 minutes at room temperature (18 – 25°C), protected from light.
4. Then perform lysis of the red cells, if necessary, by following the recommendations of the lysis reagent used. As an example, if you wish to use VersaLyse (Ref. A09777), refer to the leaflet and follow preferably the procedure called "with concomitant fixation", which consists of adding 1 mL of the "Fix-and-Lyse" mixture prepared extemporaneously. Vortex immediately for one second and incubate for 10 minutes at room temperature, protected from light. If the sample does not contain red cells, add 2 mL of PBS.
5. Centrifuge for 5 minutes at 150 x g at room temperature.
6. Remove the supernatant by aspiration.
7. Resuspend the cell pellet using 3 mL of PBS.
8. Repeat step 5.
9. Remove the supernatant by aspiration and resuspend the cell pellet using:
  - 0.5 mL or 1 mL of PBS plus 0.1% of formaldehyde if the preparations are to be kept for more than 2 hours and less than 24 hours. (A 0.1% formaldehyde PBS can be obtained by diluting 12.5 µL of the IOTest 3 Fixative Solution (Ref. A07800) at its 10X concentration in 1 mL of PBS).
  - 0.5 mL or 1 mL of PBS without formaldehyde, if the preparations are to be analyzed within 2 hours.

**NOTE:** In all cases, keep the preparations between 2 and 8°C and protected from light.

## PERFORMANCE

### SPECIFICITY

The monoclonal antibody (mAb) P2 recognizes an epitope of the CD41 molecule (gpIIb), which is dependant on the expression of the gpIIb-IIIa complex formed with the CD61 glycoprotein (gpIIIa) (3, 4). As a result, the P2 clone immunoprecipitates the gpIIb-IIIa complex with a molecular weight of 95-160 kDa (5). MAb P2 blocks the fixation of fibrinogen and inhibits platelet aggregation induced by thrombin, collagen and ADP (4).

MAb P2 was assigned to CD41 during the 3<sup>rd</sup> HLDA Workshop on Human Leucocyte Differentiation Antigens, Oxford, England, held in 1986 (WS Code: 854, Section P) (5).

### LINEARITY

To test the linearity of staining of this reagent, a positive cell line (HEL) and a negative cell line (FRN 17.4.14.33) were mixed in different proportions with a constant final number of cells, so that the positive line/negative line ratio of the mixture ranged from 0 to 100%.

Aliquots were stained using the procedure described above and linear regression between the expected values and the observed values was calculated.

Specificity	Linear regression	Linearity (R <sup>2</sup> )
CD41	Y = 0.99 X + 1.94	0.9994

### EXPECTED VALUES

The CD41 antigen is not expressed on leucocytes taken from normal blood, which does not permit a measurement of the laboratory variability of this parameter to be established from leucocytes taken from peripheral blood.

### INTRA-LABORATORY REPRODUCIBILITY

On the same day and using the same cytometer, 12 measurements of the percentage of staining of a positive target (platelets) were

carried out. The results obtained are summarized in the following table:

Positive Target	Number	Mean (%)	SD	CV (%)
Platelets CD41 <sup>+</sup>	12	82.91	2.15	2.6

### INTER-LABORATORY REPRODUCIBILITY

On the same day and for the same positive target (platelets), 12 measurements of the percentage of stained cells were carried out by two technicians and the preparations analyzed using two different cytometers. The results obtained are summarized in the following tables:

Cytometer n° 1:

Positive Target	Number	Mean (%)	SD	CV (%)
Platelets CD41 <sup>+</sup>	12	82.91	2.15	2.6

Cytometer n° 2:

Positive Target	Number	Mean (%)	SD	CV (%)
Platelets CD41 <sup>+</sup>	12	78.42	2.05	2.6

### LIMITATIONS OF THE TECHNIQUE

1. Flow cytometry may produce false results if the cytometer has not been aligned perfectly, if fluorescence leaks have not been correctly compensated for and if the regions have not been carefully positioned.
2. It is preferable to use a RBC lysis technique with a washing step as this reagent has not been optimized for "no wash" lysis techniques.
3. Accurate and reproducible results will be obtained as long as the procedures used are in accordance with the technical insert leaflet and compatible with good laboratory practices.

4. The conjugated antibody of this reagent is calibrated so as to offer the best specific signal/non-specific signal ratio. Therefore, it is important to adhere to the reagent volume/sample volume ratio in every test.
5. In certain disease states, such as severe renal failure or haemoglobinopathies, lysis of red cells may be slow, incomplete or even impossible. In this case, as in the case of low platelet counts, it is preferable to carry out the test on platelet-enriched plasma (PEP).

### MISCELLANEOUS

See the Appendix for examples and references.

### TRADEMARKS

The Beckman Coulter logo, COULTER, EPICS, EXPO, Flow-Set, IOTest, System II, VersaLyse, and XL are registered trademarks of Beckman Coulter Inc.

BD FACScan is a registered trademark of BD Biosciences and Company.

### MANUFACTURED BY:

IMMUNOTECH SAS  
a Beckman Coulter Company  
130 avenue de Lattre de Tassigny  
B.P. 177 – 13276 Marseille Cedex 9  
France  
Customer Services: (33) 4 91 17 27 27

[www.beckmancoulter.com](http://www.beckmancoulter.com)




## APPENDIX TO REF A07781


### EXAMPLES

The graphs below are monoparametric representations (Count vs. Fluorescence of normal platelet-rich plasma PRP). Staining is with IOTest CD41-PE Conjugated Antibody (Ref. A07781). Gate is on platelets. A mouse PE-conjugated IgG1 isotypic control (Ref. A07796) is shown in light.

Acquisition and analysis are performed with a COULTER® EPICS® XL™ flow cytometer equipped with System II™ software.



Acquisition is with a Becton Dickinson FACScan™ flow cytometer.



### REFERENCES

1. Rothe, G., Schmitz, G., Adorf, D., Barlage, S., Gramatzki, M., Höffkes, H.G., Janossy, G., Knüchel, R., Ludwig, W.D., Nebe, T., Nerl, C., Orfao, A., Serke, S., Sonnen, R., Tichelli, A., Wörmann, B., "Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies", 1996, *Leukemia*, 10, 877-895.
2. Phillips, D.R., Charo, I.F., Parise, L.V., Fitzgerald, L.A., "The platelet membrane gpIIb/IIIa complex", 1988, *Blood*, 71, 831-843.
3. Honda, S., Felding-Habermann, B., Loftus, J., Annis, D., Kunicki, J., "CD41/CD61 cluster report: localization of epitopes on integrins  $\alpha$ IIb $\beta$ 3 (CD41/CD61) and  $\alpha$ v $\beta$ 3 (CD51/CD61)", 1995, *Leucocyte Typing V, White Cell Differentiation Antigens*. Schlossman, S.F., et al., Eds., Oxford University Press, p. 1293-1298.
4. McGregor, J.L., Brochier, J., Wild, F., Follea, G., Trzeciak, M.C., James, E., Dechavanne, M., McGregor, L., Clemetson, K.J., "Monoclonal antibodies against platelet membrane glycoproteins. Characterization and effect on platelet function", 1983, *Eur. J. Biochem.*, 131, 427-436.
5. Horton, M.A., Hogg, N., "Platelet antigens: new and previously defined clusters", 1987, *Leucocyte Typing III, White Cell Differentiation Antigens*, A.J. McMichael, p. 733-746.